H-Index
38
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
MSMbanner

AmJCaseRep
MedSciTechnol

eISSN: 2329-0358

Potential role of immunoablation and hematopoietic cell transplantation in the treatment of early diabetes type 1

Emilian Snarski, Alicja Milczarczyk, Edward Franek, Wieslaw Wiktor Jedrzejczak

Ann Transplant 2010; 15(3): 75-79

ID: 881175

Available online:

Published: 2010-09-28


Immunoablation with autologous hematopoietic cell transplantation has shown some effectiveness in the treatment of autoimmune diseases as diverse as aplastic anemia, systemic lupus erythematosus, multiple sclerosis and Crohn’s disease. It has been recently shown that this treatment might prevent or delay development of diabetes type 1. The majority of more than 30 patients with early diabetes type 1 who underwent immunoablation and hematopoietic cell transplantation in various centers in the world achieved durable remission of diabetes and independence of exogenous insulin. This review summarizes advantages and risks of this treatment of early diabetes type 1.

Keywords: Bone Marrow Transplantation, diabetes mellitus type 1, immunoablation



Back